Scientific Program
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Scientific Program
www.iscort.org.il Scientific Program 08.01.2019 - 12.01.2019, Eilat, Israel The Annual Meeting of The Israeli Society for Clinical Oncology and Radiation Therapy ISCORT wishes to express its gratitude to the following companies הוועדה המארגנת for their support of the 19th ISCORT Annual Meeting: Organizing Committee ISCORT 19 נשיא הכנס: :President פרופ׳ סלומון שטמר Platinum Sponsor Salomon M. Stemmer, MD Roche מזכירת הכנס: :Secretory ד״ר ולריה סמניסטי Gold Sponsor Valeria Semenysty, MD יו"ר הרדיותרפיה: :BMS Radiation Oncology Co-Chair פרופ׳ בן קורן MSD Ben W. Corn, MD הוועדה המדעית Silver Sponsor Scientific Committee ISCORT 19 Astellas יו"ר: פרופ׳ מיכל לוטם Astrazeneca Chairman: Michal Lotem, MD ד"ר אהרון אלון Boehringer Ingelheim Aaron Allen, MD ד"ר נועם אסנה Eli Lilly Noam Asna, MD ד"ר יאיר בר ISI Jair Bar, MD PhD ד"ר יהונתן כהן Novartis Yonathan Cohen, MD PhD פרופ׳ בן קורן Pfizer Ben W. Corn, MD ד"ר אלה עברון Rafa Ella Evron, MD ד"ר דניאלה כץ Daniela Katz, MD פרופ׳ גל מרקל Bronze Sponsor Gal Markel, MD PhD ד"ר אינה אוספובט AbbVie Inna Ospovat, MD ד"ר אביבית פאר Assuta Avivit Peer, MD ד"ר רות פרץ Bayer Ruth Perets, MD PhD Bolpharma ד"ר רפאל פפר Raphael Pfeffer, MD Dexcel Pharma ד"ר קרן רובינוב Keren Rouvinov, MD Isotopia ד"ר יקטרינה שולמן Katerina Shulman, MD Medison ד"ר אמיר זוננבליק Merck Amir Sonnenblick, MD ד"ר מרק ויגודה Nanostring Marc Wygoda, MD ד"ר אלונה זר Neopharm Alona Zer, MD ד"ר אביעד זיק Oncotest-Teva Aviad Zik, MD Perrigo החברה המארגנת Sanofi Organizing Company א.מ. -
Rare Cause of Abdominal Pain in Cystic Fibrosis
BMJ Case Reports: first published as 10.1136/bcr-2013-201259 on 12 November 2013. Downloaded from Images in… Transient intussusception: rare cause of abdominal pain in cystic fibrosis Suheil Artul,1,2 Faozi Artoul,3 George Habib,4 Nabil Abboud5 1Department of Radiology, DESCRIPTION Nazareth Hospital, Nazareth, A 26-year-old man with history of cystic fibrosis, Israel 2Faculty Medicine in the presented to the emergency department with a Galilee, Bar-Ilan University, 2-day history of abdominal pain, nausea and vomit- Safed Israel, Maghar, Israel ing. The patient did not have a history of abdom- 3 Department of Nuclear inal surgery. Medicine, Meir Hospital, On presentation the patient was afebrile and Maghar, Israel 4Department of Medicine, normotensive. Abdominal examination revealed Nazareth Hospital, Nazareth, tenderness in the mid-abdomen and no rebound. Israel Laboratory tests showed slight leucocytosis and 5 Department of Surgery, normal level of amylase. Abdominal plain radio- Nazareth Hospital, Nazareth, Israel graph showed gaseous distention of multiple small bowel loops. Contrast CT of the abdomen showed Correspondence to total fatty replacement of the pancreas (figure 1, Dr Suheil Artul, white arrows), dilated small bowel loops up to [email protected] 4.5 cm in diameter (figure 2, red arrows) and a ‘solid mass’ of 6 cm in long axis ‘cobra head sign’ Figure 2 Contrast-enhanced CT of the abdomen showing (figure 2, black arrows) indicating ileo-ileal intus- dilated small bowel loops up to 4.5 cm in diameter (red susceptions, without any sign of bowel wall suffer- arrows), a ‘solid mass’ of6cminlongaxis‘cobra head sign’ ing such as air or oedema of the involved loop. -
Around the Globe Israeli Medical Association No
Around The Globe Israeli Medical Association No. 16 | June 2011 A word from the chairman Dear Friends, vices to those from evacuated areas who and opinions on professional issues as e are happy to present you had no access to medical care. well as on the unbalanced exposures and with another issue of ‘IMA I had the pleasure of travelling to discussions of political topics concerning around the Globe’ where the UK, and met our Jewish Medical As- Israel in the British scientific Journals. I Wyou can read about the work of the IMA sociation - UK Chapter. I met medical would like to thank the IMA UK Chapter in Israel and abroad. In February, the students affiliated with the IMA and re- for their generous hospitality during my IMA publically announced our launch viewed Neuroscience practice in Israel. time in London. of “a mission to save public medicine,” I attended an evening event hosted by I am excited to inform you that we demanding additional manpower, more Dr. David Katz, the executive chairman have been invited to present Israeli and beds in hospitals, and incentive pay to of the UK Chapter, which was attended Jewish Medicine at the European Par- draw more physicians to the periphery by the local IMA-WF committee group. liament this November. I would like to and to multiple specialties suffering Throughout the evening we discussed thank Dr. Willie Lipschutz, the executive from physician shortages. This struggle issues related to how Israeli medicine chairman of the Belgian Chapter of IMA- is for health and medicine in Israel and is portrayed in British medical journals, WF for organizing the event. -
Israel Endocrine Society
Israel Endocrine Society Israel Endocrine Society Conference Browse the program for the upcoming event By Session All Sessions By ID 4 By Day Tuesday By Author Aizic, A. - 31 Now Viewing: All Sessions Note: The presenter's name is in bold Registration Tuesday Morning Date: Tuesday, April 9, 2013 Time: 7:30 AM - 8:00 AM Location: Oral Presentations I: Diabetes, Obesity and Metabolism Date: Tuesday, April 9, 2013 Time: 8:00 AM - 10:00 AM Location: Bareket Hall Session Chair: Benjamin Glaser Session Chair: Hannah Kanety 8:00 AM - AMPK corrects ER morphology and function in stressed pancreatic beta-cells via regulation of the ER resident protein DRP1 (ID: 25) Jakob Wikstrom (Israel) Tal Israeli (Israel) Etty Bachar-Wikstrom (Israel) Yafa Ariav (Israel) Erol Cerasi (Israel) Gil Leibowitz (Israel) 8:15 AM - Paradox In Metabolic Homeostasis: AHNAK Knockout Mice Are Resistant To Diet-Induced Obesity And Yet They Display Reduced Insulin Sensitivity (ID: 47) Maya Ramdas (Israel) Chava Harel (Israel) Natalia Krits (Israel) http://www.xcdsystem.com/ies2013/Program/index.cfm[05/04/2013 11:15:55] Israel Endocrine Society Michal Armoni, Rambam Medical Center (Israel) Eddy Karnieli, Institute of Endocrinology, Metabolism and Diabetes (Israel) 8:30 AM - Neonatal Wolfram syndrome: novel De-novo dominant mutation presenting as an unusual clinical phenotype (ID: 52) Abdulsalam Abu-Libdeh, Hadassah Hebrew University Hospital (Israel) 8:45 AM - Importance of maintaining redox potential balance in the development of type 2 diabetes (ID: 61) Tovit Rosenzweig, -
Dear Colleagues, It Is Our Pleasure to Invite You to the Annual Meeting Of
Dear Colleagues, It is our pleasure to invite you to the Annual Meeting of the Israel Neurosurgical Society which will be held at the Galilion Hotel, Israel. Although the main focus of the meeting will be Brain Tumors, the organizers will be happy to consider interesting talks on related subjects. Confirmed speakers to date that will share their experiences and update us in the latest developments include: Prof. Volker A. Coenen Dept. of Stereotactic and Functional Neurosurgery, University of Freiberg; Neurosurgery Clinic, Freiberg, Germany Prof. Garth Rees Cosgrov Dept. of Neurological Surgery, Brigham and Women's Hospital, Boston, MA, USA Prof. Hans Henkes Neuroradiological Clinic, Katharinenhospital, Stuttgart, Germany Prof. Robert H. Rosenwasser Dept. of Neurological Surgery, Jefferson Hospital for Neuroscience, Philadelphia, PA, USA As in previous meetings, we hope that this event will provide the opportunity to reconnect and meet with colleagues and to strengthen professional and personal ties among our members. We hope that you will be able to join us. Sincerely, Prof. Yigal Shoshann Prof. Mony Benifla Dr. Racheli Grossman President Secretary Treasurer 1 TENTATIVE TIMETABLE Wednesday, May 13, 2020 Light Lunch Afternoon Sessions Dinner Evening Social Event Thursday, May 14, 2020 Morning Sessions Lunch Afternoon Sessions Dinner Evening Social Event Friday, May 15, 2020 Morning Sessions Afternoon Sessions End and Light Lunch Meeting Secretariat Target Conferences Ltd. PO Box 51227, Tel Aviv 6713818, Israel Tel: +972 3 5175150, Fax: +972 3 5175155 e-mail: [email protected] www.israelneurosurgery.com 2 SCIENTIFIC ADVISORY COMMITTEE ON FUNCTIONAL NEUROSURGERY AND EPILEPSY Zvi Israel - Lead Advisor Dept. of Neurosurgery, Hadassah Hebrew University Medical Center, Jerusalem Roberto Spiegelmann Dept. -
Recurrent Deep Venous Thrombosis in a Patient with Agenesis of Inferior Vena Cava
International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article CASE REPORT Recurrent deep venous thrombosis in a patient with agenesis of inferior vena cava William Nseir1 Background: Agenesis of the inferior vena cava (IVC) as a cause of recurrent deep vein Mahmud Mahamid1 thrombosis (DVT) is uncommon. Zuhair Abu-Rahmeh2 Case: A 33-year-old male with no family history of thrombophilia, who had experienced mul- Arieh Markel3,4 tiple recurrent episodes of DVT over a 15-year period of unknown cause, was admitted into our hospital because of cellulitis in the right leg. Computer tomography with contrast of the 1Department of Internal Medicine, 2Radiology Department, Holy abdomen showed an absence of IVC. Family Hospital, Nazareth, Israel; Conclusion: Congenital absence of the IVC could be a rare risk factor for idiopathic DVT, 3 Department of Internal Medicine A, especially in young individuals. Haemek Medical Center, Afula, Israel; 4Technion, Faculty of Medicine, Haifa, Keywords: deep vein thrombosis, agenesis, inferior vena cava Israel Background Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism, has an incidence of 1 to 3 per 1000 individuals per year in Western populations.1 Congenital anomalies of the inferior vena cava (IVC) are uncommon, and have been associated with the development of venous thrombosis of the lower limbs.2 Congenital anomalies of the IVC has been reported as a risk factor for DVT, especially in individuals ,30 years old, and a concomitant thrombophilic disorder has been found in such individuals.3 We report a case of recurrent DVT in a 33-year-old man with agenesis of the IVC. -
Cardiology in Poland — a European Perspective
Kardiologia Polska 2014; 72, 2: 116–121; DOI: 10.5603/KP.2014.0027 ISSN 0022–9032 OKOLICZNOŚCIOWY ARTYKUŁ REDAKCYJNY / ANNIVERSARY EDITORIAL Cardiology in Poland — a European perspective Thomas F. Lüscher, Miłosz Jaguszewski Editorial Office of the European Heart Journal, Zurich Heart House, Zürich, Switzerland THE BEGINNING in the 1960s [2]. His reports were published long before later The Polish Cardiac Society (PCS) was founded in February technical developments allowed for its use in clinical practice 1954, just a few years after the initiation of the European [2]. During the 50th anniversary of the ESC, Tadeusz Cieszyński Society of Cardiology (ESC) on September 2, 1950. The first represented inventors from Poland at the poster exhibition. president of the PCS was between 1954 and 1961 Jerzy On November 5, 1985, Zbigniew Religa (1938–2009) Jakubowski (Fig. 1A), although before hand a Working Group (Fig. 1D) performed the first successful heart transplantation of Cardiology of the Polish Society of Internal Medicine existed at the Silesian Center for Heart Diseases in Zabrze. He was with Mściwój Semerau-Siemianowski, president (Fig. 1B). a prominent cardiac surgeon, scientist and politician. In 1964, Mściwój Semerau-Siemianowski together with Izabela he had completed his medical studies. After graduating and Krzemińska-Ławkowiczowa pioneered cardiac catheterisation military service he joined the Wolski Hospital in Warsaw where in Poland as early as 1948. Since 1954 Jerzy Jakubowski, was he trained in surgery. In the 70s he held internships in the field followed by 14 other eminent Polish cardiologists as presidents of vascular surgery and cardiac surgery in the Mercy Hospital in of the PCS (Table 1). -
Curriculum Vitae – Barak Zafrir
Curriculum Vitae – Barak Zafrir PERSONAL DETAILS Date Prepared: November 2016 Name: BARAK ZAFRIR Office Address: Cardiovascular Department, Lady Davis Carmel Medical Center 7 Michal St., Haifa, Israel. Home Address: 6/6 Moshe Dayan St. , Kiryat Tiveon , Israel Phone: +972-0522541577 Email: [email protected] FAX: +972-99560390 Place of Birth: ISRAEL Date of Birth June 11, 1974 Marital Status Married; 2 Children ACADEMIC DEGREES Faculty of Medicine, Technion, 1996-2002 M.D Medicine Israel Institute of Technology, Haifa, Israel. PROFESSIONAL EXPERIENCE 2015-present Director, Cardiac Prevention and Rehabilitation Service Carmel Medical Center, Haifa, Israel 2013-present Preventive Cardiology / Lipid Clinics (a) Carmel Medical Center, Haifa, Israel. (b) Acre, Clalit Health Services, Haifa and Western Galilee District. 1 2012-2013 Advanced Clinical/Research Fellowship: Preventive Cardiology and Cardio-metabolic Diseases Brigham & Women's Hospital, Harvard Medical School, Boston, USA, [Fellowship Director: Jorge Plutzky M.D] 2010-present Staff Cardiologist Cardiovascular Department, Carmel Medical Center, Haifa, Israel 2004-2010 Residency and Fellowship: Internal Medicine and Cardiology Carmel Medical Center, Haifa, Israel. 2003 Internship: Medicine and Surgery HaEmek Medical Center, Afula, Israel. PROFESSIONAL COURSES Oct. 2016 Advanced Course on Familial Hypercholesterolemia, European Atherosclerosis Society, Greece Dec. 2015 Hyperlipidemia Academy, Amgen Co., Geneva, Switzerland. Nov. 2014 Cardiopulmonary Exercise Testing Training Course, -
State of the //ART// of the State
State of the //ART// of the State A Political Economy of Assisted Reproduction in Palestine/Israel Sigrid Vertommen Dissertation submitted in fulfillment of the requirements for the degree of Doctor in Political and Social Sciences, option Political Sciences. Middle East and North Africa Research Group - Department of Conflict and Development Studies, Ghent University March 2017 Supervisor: Prof. dr. Sami Zemni Cover design by Aïlien Reyns TABLE OF CONTENTS Summary ................................................................................................................................................................................ v Samenvatting ..................................................................................................................................................................... vi List of Abbreviations ...................................................................................................................................................... vii List of Figures .................................................................................................................................................................... ix Acknowledgements ......................................................................................................................................................... xi Introduction ....................................................................................................................................................... 1 State of the ART ............................................................................................................................................................ -
Antibiotic Treatment for Invasive Listeriosis and Patient
Antibiotic treatment for invasive listeriosis and patient outcome: a retrospective cohort study Yaakov Dickstein1, Yonatan Oster2, Orit Shimon3, Lior Nesher4, Dafna Yahav3,5, Yonit Wiener-Well6, Regev Cohen7,8, Ronen Ben-Ami3,9, Miriam Weinberger3,10, Galia Rahav3,11, Yasmin Maor3,12, Michal Chowers3,13, Ran Nir-Paz2, Mical Paul1,8 1 Institute of Infectious Diseases, Rambam Health Care Campus, Haifa, Israel 2 Department of Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center, Jerusalem, Israel 3 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 4 Infectious Disease Institute, Soroka Medical Center, Ben-Gurion University of the Negev, Beer Sheba, Israel 5 Infectious Diseases Unit, Rabin Medical Center, Beilinson hospital, Petah-Tikva, Israel 6 Infectious Disease Unit, Shaare Zedek Medical Center, Jerusalem, Israel 7 Infectious Diseases Unit, Sanz Medical Center–Laniado Hospital , Netanya, Israel 8 The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel 9 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel 10 Infectious Diseases Unit, Assaf Harofeh Medical Center, Zerifin, Israel 11 Infectious Disease Unit, Sheba Medical Center, Ramat Gan, Israel 12 Infectious Disease Unit, Wolfson Medical Center, Holon, Israel 13 Infectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel Cumulative survival by treatment group Background: Current treatment started within 48 hours of culture recommendations for treatment of results and continued for a minimum duration invasive listeriosis suggest ampicillin- of 7 days. Patients who died within 48 hours of based therapy with the addition of an the index culture were excluded. The primary aminoglycoside. However, several outcome was 30-day all-cause mortality. -
JOHNS HOPKINS UNIVERSITY ORAL HISTORY PROGRAM Myron
JOHNS HOPKINS UNIVERSITY ORAL HISTORY PROGRAM Myron Weisfeldt Interviewed by Jennifer Kinniff September 24, 2015 Johns Hopkins University Oral History Program Interviewee: Myron Weisfeldt Interviewer: Jennifer Kinniff Subject: Life of Myron Weisfeldt Date: September 24, 2015 JK: Today is September 24, 2015. This is Jenny Kinniff, Program Manager of Hopkins Retrospective. I'm here today with Dr. Myron Weisfeldt, Johns Hopkins alumnus and professor, physician, and administrator of Johns Hopkins Medicine. Thank you for being here today. MW: It's a pleasure. JK: Could we start by talking about your family and your early life? MW: Sure. I was born in Milwaukee, Wisconsin. My father was a primary care physician, a real doctor. Not like me. My mother was a school teacher. During medical school, I married Linda, my wife, who is also a school teacher. I can assure you she had a big contribution and she used her professional teaching skills to keep me in line from time to time. I have three daughters, who are also doing well and supportive. One of them is actually in the video business. She produces for CNN in Denver and is in the media. We enjoy biking and being on the Eastern Shore, and I even enjoy skiing even now. JK: What was it like – your education in Milwaukee – when did your interest in medicine develop? MW: I sort of floated into it. My father was very vigorous and active. He delivered babies, set fractures and took care of heart attacks. And I got interested in heart attacks and why people died, even in high school. -
Implantable Cardioverter Defibrillators
CME Cardiology Implantable an MI and heart failure with significant left ventricular systolic dysfunction con- tinue to have a high rate of SCD. cardioverter The first implantable cardioverter defibrillator (ICD) to manage SCD was defibrillators implanted in a human by Michel Mirowski in 1980 (Fig 1). Since then there has been an explosion in technology and Stuart Harris BSc(Hons) MBBS MRCP(UK), randomised control trial data to support Consultant Cardiologist, Essex Cardiothoracic their use. Centre, Basildon and Thurrock University Hospitals NHS Foundation Trust Mehul Dhinoja BSc(Hons) MBBS MRCP(UK), What are the components of an Specialist Registrar in Cardiology, The Heart implantable cardioverter Hospital, University College London Hospitals defibrillator? NHS Foundation Trust An ICD comprises: Clin Med 2007;7:397–400 • a lithium silver vanadium oxide Fig 1. Michel Mirowski MD (1924–90). battery, which provides low voltage energy patients with symptomatic heart failure Who needs an implantable a transformer which multiplies this • and dyssynchrony of ventricular contrac- cardioverter defibrillator? voltage tion a further lead can be placed in the In the UK, sudden cardiac death (SCD) • an aluminium electrolytic capacitor lateral tributaries of the coronary sinus occurs in 70,000–100,000 patients annu- which can store the high energy for cardiac resynchronisation (Fig 2). ally, mainly caused by ventricular voltage for use, and The basic detection of ventricular arrhythmias. Most of these patients have • sensing circuitry which can sense arrhythmias involves measuring heart recognised heart disease with either a local electrograms and filter out rate above which therapy will be deliv- previous myocardial infarction (MI) or noise like skeletal myopotentials.